The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10081 malaria professionals are enjoying the free benefits of MalariaWorld today

artemisinin-based combination therapy (ACT)

Watching the availability and use of rapid diagnostic tests (RDTs) and artemisinin-based combination therapy (ACT)

May 3, 2017 - 08:42 -- Open Access
Author(s): 
Richard W. Steketee and Thomas P. Eisele
Reference: 
Malaria Journal 2017 16:165, 24 April 2017

At the turn of this new century and after much debate, the malaria community reckoned with failing first line therapies and moved to a global recommendation for deployment of an artemisinin-based combination therapy (ACT) to treat infections due to Plasmodium falciparum.

Efficacies of DHA–PPQ and AS/SP in patients with uncomplicated Plasmodium falciparum malaria in an area of an unstable seasonal transmission in Sudan

April 26, 2017 - 15:35 -- Open Access
Tags: 
Author(s): 
Abdelrahim O. Mohamed, Muzamil M. Abdel Hamid, Omer S. Mohamed, Nuha S. Elkando, Abdelmaroof Suliman, Mariam A. Adam, Fahad Awad Ali Elnour and Elfatih M. Malik
Reference: 
Malaria Journal 2017 16:163, 20 April 2017

DHA–PPQ is an efficacious ACT and candidate for replacement of first-line treatment in Sudan while AS/SP showed high treatment failure rate and must be replaced.

Country: 

Molecular surveillance of Plasmodium falciparum drug resistance in the Republic of Congo: four and nine years after the introduction of artemisinin-based combination therapy

April 25, 2017 - 15:54 -- Open Access
Author(s): 
Felix Koukouikila-Koussounda, Sankarganesh Jeyaraj, Christian N. Nguetse, Charles Nchotebah Nkonganyi, Kossiwa Clarisse Kokou, Mandingha K. Etoka-Beka, Francine Ntoumi and Thirumalaisamy P. Velavan
Reference: 
Malaria Journal 2017 16:155, 19 April 2017

The implementation of ACT has led to the decline in prevalence of chloroquine-resistant parasites in the Republic of Congo.

The end of a dogma: the safety of doxycycline use in young children for malaria treatment

April 18, 2017 - 15:30 -- Open Access
Author(s): 
Tiphaine Gaillard, Sébastien Briolant, Marylin Madamet and Bruno Pradines
Reference: 
Malaria Journal 2017 16:148, 13 April 2017

Anti-malarial drug resistance to chloroquine and sulfadoxine–pyrimethamine has spread from Southeast Asia to Africa.

Therapeutic efficacy and artemisinin resistance in northern Myanmar: evidence from in vivo and molecular marker studies

April 11, 2017 - 15:50 -- Open Access
Tags: 
Author(s): 
Moe Kyaw Myint, Charlotte Rasmussen, Aung Thi, Dorina Bustos, Pascal Ringwald and Khin Lin
Reference: 
Malaria Journal 2017 16:143, 7 April 2017

The efficacy of AL, AS + MQ and DP remains high in northern Myanmar despite widespread evidence of k13 mutations associated with delayed parasite clearance.

Country: 
Medical Condition: 

Confirmation of Plasmodium falciparum in vitro resistance to monodesethylamodiaquine and chloroquine in Dakar, Senegal, in 2015

March 21, 2017 - 16:15 -- Open Access
Author(s): 
Silman Diawara, Marylin Madamet, Bruno Pradines, et al.
Reference: 
Malaria Journal 2017 16:118, 16 March 2017

The establishment of a reduced susceptibility to monodesethylamodiaquine as well as chloroquine resistance, and the emergence of a reduced susceptibility to doxycycline are disturbing.

Country: 
Medical Condition: 

In vivo efficacy of top five surveyed Ghanaian herbal anti-malarial products

March 9, 2017 - 15:49 -- Open Access
Tags: 
Author(s): 
Dennis Wilmot, Elvis Ofori Ameyaw, Daniel Amoako-Sakyi, Johnson Nyarko Boampong and Neils Ben Quashie
Reference: 
Malaria Journal 2017 16:103, 4 March 2017

Popular anti-malarial HPs used in southern Ghana were found to have chemo-suppressive properties.

Country: 

Optimal price subsidies for appropriate malaria testing and treatment behaviour

November 8, 2016 - 17:14 -- Open Access
Tags: 
Author(s): 
Kristian Schultz Hansen, Tine Hjernø Lesner and Lars Peter Østerdal
Reference: 
Malaria Journal 2016 15:534, 4 November 2016

A combined subsidy on both RDT and ACT rather than a single subsidy is likely required to improve diagnosis-treatment behaviour among individuals seeking care for malaria in the private sector.

Eliminate now: seven critical actions required to accelerate elimination of Plasmodium falciparum malaria in the Greater Mekong Subregion

October 26, 2016 - 17:34 -- Open Access
Author(s): 
Andrew A. Lover, Roly Gosling, Richard Feachem and Jim Tulloch
Reference: 
Malaria Journal 2016 15:518, 21 October 2016

The emergence in 2009 of Plasmodium falciparum parasites resistant to the primary therapies currently in use (artemisinin-based combination therapy, ACT) in Southeast Asia threatens to set back decades of global progress in malaria control and elimination.

Failure of dihydroartemisinin plus piperaquine treatment of falciparum malaria by under-dosing in an overweight patient

September 21, 2016 - 17:39 -- Open Access
Author(s): 
Jean Baptiste Roseau, Bruno Pradines, Nicolas Paleiron, Serge Vedy, Marylin Madamet, Fabrice Simon and Emilie Javelle
Reference: 
Malaria Journal 2016 15:479, 20 September 2016

This case confirms the risk of therapeutic failure with dihydroartemisinin–piperaquine by under-dosing in patients weighing more than 100 kg.

Pages

Subscribe to RSS - artemisinin-based combination therapy (ACT)